Published in final edited form as:

Pediatr Crit Care Med. 2016 March ; 17(3 Suppl 1): S89–S100. doi:10.1097/PCC.0000000000000622.

Pulmonary Hypertension

John S. Kim, MD, MS¹, Julia McSweeney, RN, MSN, CPNP², Joanne Lee, PharmD BCPS³, and Dunbar Ivy, MD¹

¹Department of Pediatrics, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, Colorado

²Department of Cardiology, Harvard Medical School, Children's Hospital Boston, Boston, Massachusetts

³Departments of Pharmacy and Pediatrics (Cardiology), Stanford University, Lucile Packard Children's Hospital, Palo Alto, California

Abstract

Objective—Review the pharmacologic treatment options for pulmonary arterial hypertension (PAH) in the cardiac intensive care setting and summarize the most-recent literature supporting these therapies.

Data Sources and Study Selection—Literature search for prospective studies, retrospective analyses, and case reports evaluating the safety and efficacy of PAH therapies.

Data Extraction—Mechanisms of action and pharmacokinetics, treatment recommendations, safety considerations, and outcomes for specific medical therapies.

Data Synthesis—Specific targeted therapies developed for the treatment of adult patients with PAH have been applied for the benefit of children with PAH. With the exception of inhaled nitric oxide, there are no PAH medications approved for children in the US by the FDA. Unfortunately, data on treatment strategies in children with PAH are limited by the small number of randomized controlled clinical trials evaluating the safety and efficacy of specific treatments. The treatment options for PAH in children focus on endothelial-based pathways. Calcium channel blockers are recommended for use in a very small, select group of children who are responsive to vasoreactivity testing at cardiac catheterization. Phosphodiesterase type 5 inhibitor therapy is the most-

Correspondence: John Kim, MD, MS, 13123 East 16th Avenue, B100, Pediatric Cardiology, Children's Hospital Colorado, Aurora, Colorado 80045, 720-777-3367, 720-777-7290, John.Kim@childrenscolorado.org.

Copyright form disclosures:

Dr. McSweeney disclosed off-label product use: No PH drug is FDA approved for pediatric use (This is noted several times throughout the manuscript). Dr. Lee disclosed off-label product use: Pulmonary Hypertension Medications in Pediatrics (Many medications are not FDA approved for Pediatrics. This is disclosed in the manuscript). Dr. Ivy has disclosed other support from The University of Colorado contracts with Actelion, Bayer, Gilead, Lilly, and United Therapeutics (Dr. Ivy to be a consultant); served on the steering committee for pediatric PH studies being performed by Actelion, Bayer, Lilly and United Therapeutics; has enrolled patients in research studies sponsored by Actelion, Bayer, Gilead, Lilly, and United Therapeutics; received financial support from the National Institutes of Health (NIH); served as a Board member of the Pulmonary Hypertension Association; received restricted financial contributions from the Jayden de Luca Foundation, the Frederick and Margaret Weyerhaeuser Foundation, and the Leah Bult Foundation to perform pediatric PH research; received support for article research from the NIH, Jayden de Luca Foundation, Frederick and Margaret Weyerhaeuser Foundation, and Leah Bult Foundation; and he disclosed off-label product use: Ambrisentan, Bosentan, Macitentan, Sildenafil, Tadalafil, Epoprostenol, Treprostinil, Iloprost. His institution received funding from Actelion, Bayer, and Gilead. Dr. Kim disclosed that he does not have any potential conflicts of interest.

commonly recommended oral treatment option in children with PAH. Prostacyclins provide adjunctive therapy for the treatment of PAH as infusions (intravenous and subcutaneous) and inhalation agents. Inhaled nitric oxide is the first line vasodilator therapy in persistent pulmonary hypertension of the newborn, and is commonly used in the treatment of PAH in the Intensive Care Unit (ICU). Endothelin receptor antagonists have been shown to improve exercise tolerance and survival in adult patients with PAH. Soluble Guanylate Cyclase Stimulators are the first drug class to be FDA approved for the treatment of chronic thromboembolic pulmonary hypertension.

Conclusions—Literature and data supporting the safe and effective use of PAH therapies in children in the cardiac intensive care is limited. Extrapolation of adult data has afforded safe medical treatment of pulmonary hypertension in children. Large multicenter trials are needed in the search for safe and effective therapy of pulmonary hypertension in children.

Keywords

pulmonary hypertension; calcium channel blockers; prostacyclin; pharmacotherapy; phosphodiesterase inhibitor; nitric oxide

Introduction

Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by a progressive increase in pulmonary vascular resistance leading to right heart failure and death. In the last decade, specific targeted therapies have been developed and have improved survival in adult patients with PAH. These therapies have also benefited children with PAH. The most common etiologies of PAH in children differ from the adult population. PAH is associated with congenital heart disease, idiopathic PAH (formerly known as primary PH), and heritable PAH in the majority of children. Unrepaired congenital heart diseases, such as ventricular septal defects or a patent ductus arteriosus and more complex diseases like truncus arteriosus or single ventricle may cause PAH. Although PAH associated with congenital heart disease resolves in most children after early surgical correction, some children develop irreversible pulmonary vascular disease. Thus, the natural history of PAH due to congenital heart disease has a wide range of survival. In contrast to children with congenital heart disease, the survival rate in children with idiopathic or heritable PAH is worse. The diagnosis of idiopathic PAH is difficult as the symptoms are non-specific and include breathlessness, syncope, or seizures. Unfortunately, there are limited data on treatment strategies in children with PAH due to the small number of randomized controlled clinical trials evaluating the safety and efficacy of specific treatments. Currently approved PAH therapies impact one of three endothelial-based pathways including nitric oxide-cGMP, prostacyclin, or endothelin-1 (Figure 1).⁽¹⁾ This statement summarizes currently available therapies based on adult data and a limited number of clinical trials in children with PAH (Table 1 and 2).

Calcium Channel Blockers

1. Physiologic rationale: Calcium channel blockers (CCBs) cause relaxation of vascular smooth muscle by inhibition of calcium influx to the cardiac and smooth muscle. Recent data suggest, CCB treatment for PAH is only indicated and

efficacious in 10–30% of children.(2) “Responders” to vasoreactivity testing at cardiac catheterization may have a good response to treatment with CCBs, but “nonresponders” should not be treated with CCBs as they are associated with worse survival and may lower cardiac output.

2. Mechanism of action: Calcium channel antagonists inhibit calcium flux into cardiac and smooth muscle by binding to the calcium channels and may have negative inotropic effects. The effects on systemic blood pressure are consequence of a dose-related decrease of systemic vascular resistance.
3. Pharmacokinetics: Pharmacokinetic data are available only for the children with pulmonary hypertension and bronchopulmonary dysplasia.(3) Nifedipine, diltiazem, and amlodipine undergo significant hepatic metabolism via the CYP3A4 enzyme system(4) and concomitant use with inhibitors of CYP3A4 should be cautioned.

Monitoring Parameters and Adverse Effects: High-dose CCB therapy has a potential risk for systemic hypotension and should be avoided in children with low blood pressure, low cardiac output or high right atrial pressure. Use in neonates and infants is controversial.

Prostacyclin

1. Physiologic rationale: Prostacyclin, a member of the endogenous prostanoid family, is a potent vasodilator and has anti-thrombotic, anti-proliferative, and anti-inflammatory effects.
2. Mechanism of action: Prostacyclin is produced from arachidonic acid in the vascular endothelium.(6) The elaborated prostacyclin has an extremely short biological half-life of between 2–3 minutes in the pulmonary circulation. The biological functions of prostacyclin are mediated by cell-surface G-protein receptors on pulmonary endothelial cells or platelets and increased intracellular cyclic adenosine monophosphate leads to smooth muscle relaxation and inhibition of platelet aggregation.(7) Prostacyclin metabolites and prostacyclin synthase are decreased in PAH.(8–10)
3. Pharmacokinetics:
 - a. Epoprostenol has a rapid onset of action, reaching plasma steady-state concentrations within 15 minutes. Epoprostenol is obligated to a continuous intravenous therapy due to the elimination half-life of 2–3 minutes. In human blood, epoprostenol is rapidly hydrolyzed and metabolized to 6-keto-PGF1 α . This metabolite is biologically inactive and eliminated in the urine.(11, 12)

Monitoring Parameters and Adverse Effects: Severe adverse events such as bradycardia, systemic hypotension, and thrombocytopenia may occur and should be monitored at initiation of administration. Patients with pulmonary veno-occlusive disease or pulmonary vein disease may develop life-threatening pulmonary edema. Patients with pneumonia or other parenchymal lung disease may develop

worsening ventilation-perfusion matching. Epoprostenol also inhibits platelet aggregation with a potentially increased risk of bleeding with concomitant anticoagulant or antiplatelet therapy.(13, 14) Serious complications of “rebound” pulmonary hypertension can occur on acute discontinuation. Dyspnea, chest pain, pallor, and syncope may result from insufficient drug delivery.

- b. Iloprost, an inhaled prostacyclin analogue, has low risk of systemic hypotension and minimizing the effect on ventilation-perfusion mismatch compared to intravenous prostacyclin.(15–21) Iloprost achieves maximum serum concentration at 5–10 minutes after inhalation. The serum elimination half-life of inhaled iloprost is 6.5–9.4 minutes with a pharmacodynamic half-life of 20–25 minutes.(22, 23) Approximately 80–90% of metabolites are eliminated in the kidney.

Monitoring parameters and adverse effects: Inhaled iloprost requires caution in patients with concomitant pulmonary disease such as asthma and interstitial lung disease. The liver and kidney metabolize iloprost, and dosage adjustments may be necessary in hepatic or renal insufficiency. No significant events of serious bleeding have been noted in patients during co-administration with warfarin. There are no significant drug-to-drug pharmacokinetic interactions between iloprost and other pulmonary vasodilators(2).

- c. Treprostinil, an alternative prostacyclin analogue, was initially approved by the FDA for subcutaneous use and subsequently approved for intravenous, inhaled, and oral use. The advantages of treprostinil therapy compared to epoprostenol include stability at room temperature, longer half-life, fewer side effects and small pump options for outpatient use.

Intravenous and subcutaneous treprostinil infusions are bioequivalent with a terminal elimination half-life of approximately 4.5 hours. Treprostinil is rapidly and completely absorbed with subcutaneous infusion. Steady-state concentrations occur in 10 hours.(24–27)

Monitoring parameters and adverse effects: Systemic blood pressure, heart rate, and side effects should be monitored with intravenous treprostinil initiation, thus requiring hospital initiation. Major side effects of treprostinil include headache, diarrhea, nausea, rash, flushing, jaw pain, and foot pain. Following transition from epoprostenol to IV treprostinil, children exhibited less prostanoid side effects, with the exception of leg/muscle pain.(28) Prostanoid side effects are similar with subcutaneous administration with the addition of infusion site pain and reaction being the most-common side effects (with a negative impact on tolerability). The clearance of treprostinil is decreased in patients with hepatic insufficiency and caution with dosing is needed in children with liver disease. Gram-negative bacteremia has been associated with

intravenous treprostinil therapy. The use of protected connections and an alkaline buffer may decrease the risk.(29, 30) Treprostinil has no pharmacokinetic interactions with endothelin receptor antagonists or phosphodiesterase inhibitors. Co-administration of treprostinil may have a potential risk of bleeding and systemic hypotension in children receiving concomitant anticoagulants or vasodilators, respectively.(31)

Inhaled treprostinil has an unknown half-life that cannot be estimated given the low plasma concentration achieved (as compared to parenteral treprostinil) due to direct lung delivery. Patients requiring rates of parenteral treprostinil 15 ng/kg/min should not be transitioned to inhaled treprostinil given the decreased exposure. Inhaled treprostinil T_{max} is achieved in 5–10 minutes.

Monitoring parameters and adverse effects: In contrast to its intravenous formulation, inhaled treprostinil has less systemic effects and has been started in the outpatient setting in stable patients as add-on therapy. Inhaled treprostinil requires caution in patients with concomitant pulmonary disease such as asthma and interstitial lung disease.(32)

Oral treprostinil was recently approved and there is little experience in children. Oral treprostinil is an osmotic tablet delivered orally. The pill must be swallowed whole and may not be chewed or broken as the entire dose will be delivered. There is no suspension. The maximum dose is determined by tolerability.

Monitoring parameters and adverse effects: Oral treprostinil may cause prostanoid side effects similar to other prostacyclins. (33)

4. Evidence to support the therapy:

- a. Epoprostenol is indicated for the treatment of adult PAH patients to improve exercise tolerance and survival.(34–36) Although epoprostenol is not approved in children, continuous intravenous epoprostenol therapy is effective for improving symptoms, hemodynamics, and survival in children with idiopathic PAH or PAH associated with congenital heart disease.(2, 37–39) Inhaled epoprostenol has been effectively used in the ICU setting in place of inhaled NO.
- b. Iloprost is indicated for adults with PAH to improve a composite endpoint consisting of exercise tolerance, functional class symptoms, and lack of deterioration.(32) Although iloprost is not approved in children, several studies have evaluated the use of aerosolized iloprost in children with PAH. (15–21) There is currently only one study showing chronic iloprost efficacy in children with idiopathic PAH or PAH associated with congenital heart disease.(16) In this study, iloprost caused sustained functional improvement in select children with PAH, however, bronchoconstriction led to

discontinuation in some patients. One small study retrospectively reviewed 7 children who transitioned from inhaled NO to inhaled iloprost in the post-operative period after congenital heart surgery. Systolic pulmonary artery (PAP) or systemic arterial (SAP) pressures did not differ between inhaled NO versus iloprost treatment but the PAP to SAP ratio was reduced on iloprost therapy (from 0.61 on NO to 0.49 on iloprost, $p=0.03$). Though this is a modest improvement, this study shows that children on inhaled NO can be successfully transitioned to inhaled iloprost therapy.(40) A prospective study in 2008 evaluated 12 children at risk for pulmonary hypertensive crisis after congenital heart surgery in whom iloprost was administered in place of inhaled NO. Eight children had a pulmonary hypertensive crisis that was responsive to inhaled iloprost with a fall in mean PAP (47.9 to 30.2, $p=0.012$) and a rise in arterial saturation (82.2 to 93.4, $p=0.012$) with no fall in systemic arterial pressure.(19)

- c. Treprostinil has four delivery options and is FDA approved for subcutaneous (2002), intravenous (2004), inhaled (2009) and oral (2013) administration in adults with PAH to diminish symptoms associated with exercise.(41–44) Treprostinil therapy is not approved in the pediatric population. However, recent studies have demonstrated safety in transitioning pediatric patients from epoprostenol to subcutaneous or intravenous treprostinil therapy for the advantages of stability at room temperature and a longer half-life as compared to epoprostenol.(28, 45) Inhaled treprostinil has been studied both in acute and long-term treatment of children.(46, 47) There are no published studies of oral treprostinil in children.

Phosphodiesterase Type 5 Inhibitors

1. Physiologic rationale: Phosphodiesterase type 5 (PDE-5) inhibitors increase the concentration of cyclic guanosine monophosphate (cGMP) in pulmonary smooth muscle vasculature, thus resulting in pulmonary vasodilation.
2. Mechanism of action: PDE-5 is abundantly expressed in lung and penile tissue; in PAH the PDE-5 enzyme is increased in the lung vasculature. PDE-5 inactivates cGMP leading to attenuated vasodilation.(48) PDE-5 inhibitors have antiproliferative, proapoptotic, and vasodilating effects in pulmonary vasculature through an increase in cGMP.(49)
3. Pharmacokinetics:
 - a. Sildenafil is absorbed rapidly after oral administration with maximum plasma concentrations achieved after 1–2 hours and a half-life of approximately 4 hours in adults. Metabolism of sildenafil occurs primarily by hepatic cytochrome P450 (CYP) enzymes such as CYP3A4 and CYP2C9. CYP3A4 inducers, and medications such as bosentan, decrease the levels of sildenafil, thus monitoring may be advisable with co-administration with CYP3A4 inducers. Alternatively, CYP3A4 inhibitors increase serum concentrations of sildenafil.

Monitoring parameters and adverse effects: Oral sildenafil has less systemic effects and has been started in the outpatient setting. Eye and hearing screening in extremely premature infants should be considered.(50–53) Hearing and visual disturbances in older patients have been described. Patients with a creatinine clearance less than 30 ml/min, hepatic cirrhosis, or concomitant use of CYP3A4 inhibitors may require a reduction in their sildenafil dose. (54) Although serum levels can rise in severe impairment of renal or hepatic function, dosage adjustments are usually not necessary. Sildenafil should not be used concomitantly with systemic nitrates. Co-administration of sildenafil with bosentan leads to decreased sildenafil plasma concentrations and increased bosentan concentrations.(55) There is no significant pharmacokinetic interaction between sildenafil and warfarin. Erections may occur in 10% of boys taking sildenafil but are usually not serious.

- b. Tadalafil reaches a maximal concentration of 2 hours with a half-life of 35 hours after oral administration in adults.(56) Steady-state plasma concentrations are achieved within 5 days of initiation of tadalafil at 20 mg or 40 mg daily. Metabolism of tadalafil occurs primarily by hepatic cytochrome P450 CYP3A4 enzyme.

Monitoring parameters and adverse effects: Use in children less than 4 years has not been described and use in neonates and infants is contraindicated due to lack of maturation of glucuronidation pathway.(57, 58) Tadalafil has little effect on PDE-6, thus has a minimal influence on visual effects. Concomitant use of potent inducers or inhibitors of CYP3A is not recommended. The dose should be reduced in patients with mild to moderate renal or hepatic impairment. Tadalafil is not recommended in patients with severe renal or hepatic disease, and should not be used in patients taking nitrates. Tadalafil exposure is decreased with concomitant bosentan by 41.5% in healthy adult volunteers.(59) Co-administration of tadalafil with bosentan leads to decreased tadalafil plasma concentrations and increased bosentan concentrations. No pharmacokinetic drug interactions between tadalafil and ambrisentan have been noted.(60)

4. Evidence to support the therapy:

- a. Sildenafil was FDA approved in 2005 for the treatment of adult PAH to improve exercise ability and delay time to clinical worsening at a dose of 20 mg TID.(61) Although sildenafil is approved for use in children with PAH in Europe, the United States FDA released a strong warning in 2012 against the chronic use of sildenafil in children with PAH with concerns for increased mortality at higher doses. The *STARTS-2* trial (an extension of the *STARTS-1* trial) is a worldwide randomized, double blind, placebo-

controlled study of 234 treatment naïve children evaluating outcomes of low (10 mg), medium (10–40 mg), or high (20–80 mg) doses of oral sildenafil or placebo TID.(62) Survival on sildenafil monotherapy was similar for the first year for all dosage groups in the *STARTS-2* study.(63, 64) At three years, however, an increase in mortality was noted at the high-dose range. Deaths were related to etiology and baseline disease severity (idiopathic and familial PAH with above-median values for PVR, mean PAP, and right atrial pressure at baseline). In response to the FDA warning, clinical pediatric PAH experts put forth a consensus statement highlighting the limitations of the *STARTS-2* extension study and recommending continued but cautious use of oral sildenafil in pediatric patients with a strong recommendation to avoid the use of high doses.(65) The FDA published a clarification in 2014 stating that the risks and benefits of sildenafil should be considered in treating children with PAH. Intravenous sildenafil has also been studied in children. A double-blind, multicenter, placebo-controlled study of intravenous sildenafil in pediatric patients with congenital heart disease and postoperative pulmonary hypertension showed favorable results such as shorter time to extubation and intensive care unit stay, although the study was stopped early due to poor enrollment.(66) Sildenafil is approved for pediatric PAH in Europe.

- b. Tadalafil, a long-acting PDE-5 inhibitor, is a once-daily oral alternative to sildenafil and was FDA approved for adults in 2009. Tadalafil is currently approved for the treatment of adult PAH (World Health Organization (WHO) Group 1) to improve exercise ability. While little is known of the use of tadalafil in children with PAH, a recent retrospective study suggested clinical efficacy and safety in children with PAH. In this study, 33 pediatric patients with PAH were retrospectively evaluated and 29 of 33 patients who transitioned from sildenafil (3.4 ± 1.1 mg/kg/day) to tadalafil (1.0 ± 0.4 mg/kg/day) successfully continued tadalafil therapy without the need to return back to sildenafil. Only 2 patients stopped tadalafil due to side effects including migraine and allergic reaction (discontinuation rate 6%). Furthermore, tadalafil statistically improved hemodynamic data including mean pulmonary arterial pressure (53.2 ± 18.3 versus 47.4 ± 13.7 , $p < 0.05$) and pulmonary vascular resistance index (12.2 ± 7.0 versus 10.6 ± 7.2 , $p < 0.05$) compared with sildenafil in 14 of 29 patients with repeated catheterization.(58)

Inhaled Nitric Oxide

1. Physiologic rationale: Inhaled Nitric oxide (NO) is the first line vasodilator treatment for persistent pulmonary hypertension of the newborn.(67–70) Similar to endogenously produced NO, inhaled NO diffuses rapidly across the alveolar-capillary membrane and induces vasodilation through a cyclic guanosine monophosphate (cGMP)-dependent pathway.(71, 72) Although FDA approval for inhaled NO therapy is restricted to newborns with hypoxemic respiratory failure,

inhaled NO has been used in management of post-operative PAH associated with congenital heart disease, congenital diaphragmatic hernia, bronchopulmonary dysplasia and severe PAH presenting with hemodynamic instability and right heart failure.(73–76)

2. Mechanism of action: NO is produced endogenously from L-arginine by NO synthases. Inhaled NO diffuses rapidly across the alveolar-capillary membrane into the pulmonary smooth muscle. The pathophysiological effects of NO are mediated through the increased intracellular concentrations of cGMP, leading to smooth muscle relaxation.
3. Pharmacokinetics: No pharmacokinetic data are available.
 - a. Dosing: NO is administered by mask, nasal cannula, or tracheal tube. A randomized, placebo-controlled, dose–response trial compared 3 different doses of inhaled NO (5, 20 or 80 ppm) and placebo in term newborns with respiratory failure. In this study, all regimens of inhaled NO improved oxygenation compared to the placebo group, however, there was no difference in responses among the 3 regimens and 35% of patients who received 80 ppm of inhaled NO had methemoglobinemia. The study suggested that 5–40 ppm of inhaled NO therapy may be appropriate and safe, while sustained treatment with 80 ppm NO increases the risk of adverse events.(77, 78)
 - b. Monitoring parameters and adverse effects: Patients receiving inhaled NO should be monitored for formation of nitrogen dioxide (NO₂) and methemoglobinemia. NO₂ is easily converted to nitric acid that is highly toxic to the respiratory tract. Methemoglobinemia may occur under high concentrations of inhaled NO (80 ppm).(77, 78) Inhaled NO combines with hemoglobin and is rapidly oxidized to methemoglobin, leading to tissue hypoxia without cyanosis. The acute withdrawal of inhaled NO therapy may precipitate rebound PAH, which may be avoided with the use of PDE-5 inhibitors. There are no known drug interactions.
4. Evidence to support the therapy: Multicenter, randomized clinical studies have demonstrated that inhaled NO reduces the need for extracorporeal membrane oxygenation in PPHN.(69) Furthermore, inhaled NO is used for the acute vasoreactivity testing during the assessment of pulmonary hemodynamics at cardiac catheterization.(16, 47, 78–80)

Endothelin Receptor Antagonists

1. Physiologic rationale: Endothelin-1 (ET-1), a potent vasoactive peptide produced primarily in the vascular endothelial and smooth muscle cells, is considered the predominant pathophysiological isoform in PAH. The over-expression of ET-1 protein has been demonstrated in patients with PAH.(81) Plasma and lung tissue ET-1 expression are increased in PAH, and correlate with the degree of pulmonary remodeling. ET-1 is a potent vasoconstrictor and is mediated by 2 types of endothelin receptors including type A (ET_A) and type B (ET_B). Bosentan shows an

almost equal affinity for both receptors. In contrast, ambrisentan is highly selective for ET_A. Bosentan and ambrisentan can improve hemodynamics and survival in adult patients with PAH. Although the use of oral bosentan in pediatric patients with idiopathic or associated PAH has been reviewed previously(82–87), bosentan has not been approved in pediatric populations.

2. Mechanism of action: The ET_A receptor and ET_B receptor on vascular smooth muscle mediates vasoconstriction and cell proliferation in pulmonary vascular smooth muscle cells. The ET_B receptor on endothelial cells mediates vasodilation, antiproliferation, and ET-1 clearance. Bosentan and macitentan are highly specific, competitive, dual ET-1 receptor antagonists which bind to ET_A and ET_B receptors. (81) Ambrisentan is a selective antagonist of ET_A with a 4000-fold greater affinity for ET_A over the ET_B receptor.(88, 89) The possible impact of higher selectivity for the ET_A receptor includes greater vasodilation and ET-1 clearance.

3. Pharmacokinetics:

- a. Bosentan: Bosentan is rapidly absorbed after oral administration and the median time to maximum plasma concentration is 1–3 hours.(82, 90) Bosentan is metabolized in the liver by CYP2C9 and CYP3A4.

Monitoring parameters and adverse effects: Bosentan has the potential risk of dose-dependent increase in aminotransferase in adults(81) but the incidence of this is low in children(84), liver function tests must be monitored monthly and bosentan should be used with caution in critically ill children with liver dysfunction. Concomitant use of bosentan with inhibitors of CYP2C9 or CYP3A4 should be cautioned.(83) The pharmacokinetics of bosentan was not affected by coadministration with warfarin, but bosentan can decrease anticoagulant response from warfarin and must be monitored closely. Because sildenafil inhibits CYP3A4 activity, the coadministration of sildenafil leads to an increase in bosentan concentrations.(91) Likewise, bosentan reduces the concentration of sildenafil. Therefore, adjusting the dose of sildenafil or bosentan should be considered in patients treated with combination therapy. Bosentan is teratogenic.

- b. Ambrisentan: Ambrisentan is rapidly absorbed after oral administration with mean time to maximal concentrations of 1.7–3.3 hours. Steady state is achieved after 3–4 days of therapy. The half-life of ambrisentan is approximately 15 hours for the 5 mg once-daily dosing in adults patients. The primary metabolic pathway of ambrisentan is hepatic glucuronidation. Ambrisentan is also metabolized by CYP3A4 and CYP2C19 isozymes.(60, 92, 93)

Monitoring parameters and adverse effects: Monthly liver function testing for ambrisentan is no longer on the FDA label after a recent study found no difference in hepatic aminotransferase level

elevation when compared to placebo(88, 89), but most pediatric centers still perform routine monitoring, every 3–4 months. Ambrisentan is partially metabolized by CYP3A4 and CYP2C19 and caution should be exercised with concomitant use of medications that are strong inhibitors of CYP3A4 or CYP2C19. Administration of ambrisentan with warfarin does not have significant drug interactions. There are no drug-to-drug interactions between ambrisentan and sildenafil.(60, 93–95) Ambrisentan should be used with caution in critically ill children with liver dysfunction. Ambrisentan is teratogenic.

- c. Macitentan: Macitentan is slowly absorbed after oral administration with time to peak concentration of 8 hours. The half-life of macitentan is approximately 16 hours (active metabolite approximately 48 hours).(96, 97) Macitentan is metabolized by CYP3A4 and CYP2C19 isoenzymes.

Monitoring parameters and adverse effects: ERAs are known to cause hepatotoxicity and liver failure; baseline liver enzymes should be obtained and monitored as clinically indicated. Macitentan is a major substrate of CYP3A4 and caution should be exercised with concomitant use of medications that are strong inhibitors or inducers of CYP3A4. Macitentan does not cause clinically relevant changes in sildenafil or warfarin exposure. There are currently no published studies in children. Macitentan is teratogenic.

4. Evidence to support the therapy:

- a. Bosentan: Bosentan, an oral endothelin ET_A/ET_B receptor antagonist, improves exercise capacity, hemodynamics, and survival in adult patients with PAH.(98–100) Bosentan was FDA approved in 2001 and is recommended as treatment for adult PAH patients. Twice-daily doses of bosentan at 31.25 mg, 62.5 mg, or 125 mg (10–20 kg, >20–40 kg, or >40 kg, respectively) for 12 weeks significantly improved hemodynamics in pediatric PAH patients (aged 3–15 years) with WHO functional class II or III in a noncomparative, multicenter, pharmacokinetic trial (*BREATHE-3*).(82) Although the use of oral bosentan in pediatric patients with idiopathic or associated PAH has shown clinical efficacy(82–87), bosentan has not been approved in pediatric populations in the United States. A pediatric formulation is approved in Europe.
- b. Ambrisentan: Ambrisentan, an oral endothelin ET_A/ET_B receptor antagonist, was approved as treatment for adult patients with PAH in 2013. Ambrisentan has demonstrated improved exercise tolerance, WHO functional class, and Borg dyspnea score in adults.(88, 91) The clinical efficacy and safety of ambrisentan therapy has not been well studied in children with PAH. A recent retrospective study suggested clinical efficacy and safety of ambrisentan in 38 children with PAH.(101)

- c. Macitentan: Macitentan, a selective oral endothelin ET_A receptor antagonist, was approved as treatment for adult patients with PAH in 2013. A trial of 250 patients revealed improved survival in patients randomized to 3 mg of macitentan daily when compared to placebo (with further improvement at 10 mg daily compared to placebo).(102) There are currently no studies in children.

Soluble Guanylate Cyclase Stimulators (Riociguat)

1. Physiologic rationale: Nitric oxide induces vasodilation through a cGMP-dependent pathway.(71, 72) Riociguat increases cGMP levels, thus inducing vasodilation of the pulmonary vasculature.
2. Mechanism of action: Riociguat stimulates soluble guanylate cyclase (sGC) independently of NO and increases the sensitivity of sGC to NO, resulting in increased cGMP levels.
3. Pharmacokinetics: Riociguat is rapidly absorbed and maximum plasma concentration is reached between 0.5–1.5 h. The mean elimination half-life is 5–10 hours.

Monitoring parameters and adverse effects: The most common serious adverse events associated with riociguat use include right ventricular failure and syncope.(103, 104) Patients should not take riociguat with any nitrates or PDE-5 inhibitors as this combination may lead to severe hypotension. Riociguat alters the regulation of bone homeostasis in juvenile rats and the riociguat-related bone findings are of concern with respect to potential pediatric use, especially in infants and younger children. Riociguat has no pharmacodynamic interaction with warfarin. (105) Riociguat is teratogenic.

4. Evidence to support the therapy: Riociguat was FDA approved in 2013 for the treatment of PAH and is the first drug to be approved for the treatment of PH associated with chronic thromboembolic pulmonary hypertension (CTEPH). In *Patent-1*, 443 patients with symptomatic PAH were randomized to receive placebo or riociguat. After 12 weeks, the riociguat group had improved 6-minute walk distance by 30 m ($P<0.001$) and the placebo group had decline by 6 months ($P<0.001$). There were also significant improvements in pulmonary vascular resistance ($P<0.001$), NT-proBNP levels ($P<0.001$), WHO functional class ($P=0.003$), and time to clinical worsening ($P=0.005$).(103) In the *CHEST-1* study, 261 patients with inoperable chronic thromboembolic pulmonary hypertension or persistent or recurrent pulmonary hypertension after pulmonary endarterectomy were randomized to receive placebo or riociguat. By week 16, the 6-minute walk distance had increased by a mean of 39 m in the riociguat group ($P<0.001$), as compared with a mean decrease of 6 m in the placebo group ($P<0.001$). Riociguat was also associated with significant improvements in the NT-proBNP level ($P<0.001$) and WHO functional class ($P=0.003$).(104)

References

1. Diller GP, Baumgartner H. Pulmonary arterial hypertension in adults with congenital heart disease. *Int J Clin Pract Suppl.* 2010; 64:13–24. [PubMed: 19958396]
2. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. *Circulation.* 1999; 99:1197–1208. [PubMed: 10069788]
3. Ma B, Prueksaritanont T, Lin JH. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. *Drug Metab Dispos.* 2000; 28:125–130. [PubMed: 10640508]
4. Flynn JT, Pasko DA. Calcium channel blockers: pharmacology and place in therapy of pediatric hypertension. *Pediatric Nephrology.* 2000
5. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. *N Engl J Med.* 1992; 327:76–81. [PubMed: 1603139]
6. Ruan K-H. Advance in understanding the biosynthesis of prostacyclin and thromboxane A2 in the endoplasmic reticulum membrane via the cyclooxygenase pathway. *Mini Rev Med Chem.* 2004; 4:639–647. [PubMed: 15279598]
7. Chow KBS, Jones RL, Wise H. Protein kinase A-dependent coupling of mouse prostacyclin receptors to Gi is cell-type dependent. *Eur J Pharmacol.* 2003; 474:7–13. [PubMed: 12909190]
8. Tudor RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. *Am J Respir Crit Care Med.* 1999; 159:1925–1932. [PubMed: 10351941]
9. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. *N Engl J Med.* 1992; 327:70–75. [PubMed: 1603138]
10. Adatia I, Barrow SE, Stratton PD, et al. Thromboxane A2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease. *Circulation.* 1993; 88:2117–2122. [PubMed: 8222105]
11. Brash AR, Jackson EK, Lawson JA, et al. Quantitative aspects of prostacyclin metabolism in humans. *Adv Prostaglandin Thromboxane Leukot Res.* 1983; 11:119–122. [PubMed: 6221513]
12. Rosenkranz B, Fischer C, Frölich JC. Prostacyclin metabolites in human plasma. *Clin Pharmacol Ther.* 1981; 29:420–424. [PubMed: 7009022]
13. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. *Circulation.* 2002; 106:1477–1482. [PubMed: 12234951]
14. Ivy D. Advances in pediatric pulmonary arterial hypertension - PubMed - NCBI. *Current Opinion in Cardiology.* 2012; 27:70–81. [PubMed: 22274573]
15. Ivy DD. Prostacyclin in the intensive care setting. *Pediatric Critical Care Medicine.* 2010; 11:S41–S45. [PubMed: 20216163]
16. Ivy DD, Doran AK, Smith KJ, et al. Short- and long-term effects of inhaled iloprost therapy in children.- PubMed - NCBI. *JACC.* 2008; 51:161–169. [PubMed: 18191742]
17. Rimensberger PC, Spahr-Schopfer I, Berner M, et al. Inhaled nitric oxide versus aerosolized iloprost in secondary pulmonary hypertension in children with congenital heart disease: vasodilator capacity and cellular mechanisms. *Circulation.* 2001; 103:544–548. [PubMed: 11157720]
18. Limsuwan A, Khosithseth A, Wanichkul S, et al. Aerosolized iloprost for pulmonary vasoreactivity testing in children with long-standing pulmonary hypertension related to congenital heart disease. *Catheter Cardiovasc Interv.* 2009; 73:98–104. [PubMed: 19089967]
19. Limsuwan A, Wanitkul S, Khosithset A, et al. Aerosolized iloprost for postoperative pulmonary hypertensive crisis in children with congenital heart disease. *Int J Cardiol.* 2008; 129:333–338. [PubMed: 18096256]
20. Beghetti M, Berner M, Rimensberger PC. Long term inhalation of iloprost in a child with primary pulmonary hypertension: an alternative to continuous infusion. *Heart.* 2001; 86:E10. [PubMed: 11514501]

21. Mulligan C, Beghetti M. Inhaled iloprost for the control of acute pulmonary hypertension in children: a systematic review. *Pediatric Critical Care Medicine*. 2012; 13:472–480. [PubMed: 21926655]
22. Krause W, Kraus T. Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. *Eur J Clin Pharmacol*. 1986; 30:61–68. [PubMed: 2423342]
23. Olschewski H, Rohde B, Behr J, et al. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. *Chest*. 2003; 124:1294–1304. [PubMed: 14555558]
24. Laliberte K, Arneson C, Jeffs R, et al. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. *J Cardiovasc Pharmacol*. 2004; 44:209–214. [PubMed: 15243302]
25. McSwain CS, Benza R, Shapiro S, et al. Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion. *J Clin Pharmacol*. 2008; 48:19–25. [PubMed: 18094217]
26. Wade M, Baker FJ, Roscigno R, et al. Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion. *J Clin Pharmacol*. 2004; 44:503–509. [PubMed: 15102871]
27. Wade M, Baker FJ, Roscigno R, et al. Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion. *J Clin Pharmacol*. 2004; 44:83–88. [PubMed: 14681345]
28. Ivy DD, Claussen L, Doran A. Transition of stable pediatric patients with pulmonary arterial hypertension from intravenous epoprostenol to intravenous treprostinil. *Am J Cardiol*. 2007; 99:696–698. [PubMed: 17317374]
29. Doran AK, Ivy DD, Barst RJ, et al. Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension. *Int J Clin Pract Suppl*. 2008;5–9. [PubMed: 18638170]
30. Ivy DD, Calderbank M, Wagner BD, et al. Closed-Hub Systems with Protected Connections and the Reduction of Risk of Catheter-Related Bloodstream Infection in Pediatric Patients Receiving Intravenous Prostanoid Therapy for Pulmonary Hypertension. *Infection control and hospital epidemiology : the official journal of the Society of Hospital Epidemiologists of America*. 2009; 30:823–829.
31. Wade M, Hunt TL, Lai AA. Effect of continuous subcutaneous treprostinil therapy on the pharmacodynamics and pharmacokinetics of warfarin. *J Cardiovasc Pharmacol*. 2003; 41:908–915. [PubMed: 12775969]
32. Olschewski H, Simonneau G, Galiè N, et al. Inhaled Iloprost for Severe Pulmonary Hypertension. *N Engl J Med*. 2002; 347:322–329. [PubMed: 12151469]
33. Jing Z-C, Parikh K, Pulido T, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. *Circulation*. 2013; 127:624–633. [PubMed: 23307827]
34. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. *N Engl J Med*. 1996; 334:296–301. [PubMed: 8532025]
35. Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. *Ann Intern Med*. 1994; 121:409–415. [PubMed: 8053614]
36. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. *Ann Intern Med*. 2000; 132:425–434. [PubMed: 10733441]
37. Lammers AE, Hislop AA, Flynn Y, et al. Epoprostenol treatment in children with severe pulmonary hypertension. *Heart*. 2007; 93:739–743. [PubMed: 17065181]
38. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. *Circulation*. 1999; 99:1858–1865. [PubMed: 10199883]

39. Ivy DD, Doran A, Claussen L, et al. Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan. *Am J Cardiol.* 2004; 93:943–946. [PubMed: 15050507]
40. Vorhies EE, Caruthers RL, Rosenberg H, et al. Use of Inhaled Iloprost for the Management of Postoperative Pulmonary Hypertension in Congenital Heart Surgery Patients: Review of a Transition Protocol. *Pediatr Cardiol.* 2014; 35:1337–1343. [PubMed: 24872141]
41. Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. *Eur Respir J.* 2006; 28:1195–1203. [PubMed: 16899485]
42. Benza RL, Seeger W, McLaughlin VV, et al. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. *J Heart Lung Transplant.* 2011; 30:1327–1333. [PubMed: 22055098]
43. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of Inhaled Treprostinil to Oral Therapy for Pulmonary Arterial Hypertension. *JACC.* 2010; 55:1915–1922. [PubMed: 20430262]
44. Tapson VF, Gomberg-Maitland M, McLaughlin VV, et al. Safety and Efficacy of IV Treprostinil for Pulmonary Arterial Hypertension: A Prospective, Multicenter, Open-Label, 12-Week Trial. *Chest.* 2006; 129:683–688. [PubMed: 16537868]
45. Gomberg-Maitland M, Tapson VF, Benza RL, et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. *Am J Respir Crit Care Med.* 2005; 172:1586–1589. [PubMed: 16151039]
46. Krishnan U, Takatsuki S, Ivy DD, et al. Effectiveness and safety of inhaled treprostinil for the treatment of pulmonary arterial hypertension in children. *Am J Cardiol.* 2012; 110:1704–1709. [PubMed: 22917554]
47. Takatsuki S, Parker DK, Doran AK, et al. Acute pulmonary vasodilator testing with inhaled treprostinil in children with pulmonary arterial hypertension. *Pediatr Cardiol.* 2013; 34:1006–1012. [PubMed: 23184020]
48. Corbin JD, Beasley A, Blount MA, et al. High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors. *Biochem Biophys Res Commun.* 2005; 334:930–938. [PubMed: 16023993]
49. Wharton J, Strange JW, Møller GMO, et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. *Am J Respir Crit Care Med.* 2005; 172:105–113. [PubMed: 15817798]
50. Skeith L, Yamashita C, Mehta S, et al. Sildenafil and furosemide associated ototoxicity: consideration of drug-drug interactions, synergy, and broader clinical relevance. *J Popul Ther Clin Pharmacol.* 2013; 20:e128–31. [PubMed: 23756362]
51. McGwin G. Phosphodiesterase type 5 inhibitor use and hearing impairment. *Arch Otolaryngol Head Neck Surg.* 2010; 136:488–492. [PubMed: 20479381]
52. Giuliano F, Jackson G, Montorsi F, et al. Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. *Int J Clin Pract.* 2010; 64:240–255. [PubMed: 19900167]
53. Maddox PT, Saunders J, Chandrasekhar SS. Sudden hearing loss from PDE-5 inhibitors: A possible cellular stress etiology. *The Laryngoscope.* 2009; 119:1586–1589. [PubMed: 19507217]
54. Muirhead GJ, Wilner K, Colburn W, et al. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. *Br J Clin Pharmacol.* 2002; 53(Suppl 1):21S–30S. [PubMed: 11879256]
55. Burgess G, Hoogkamer H, Collings L, et al. Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil. *Eur J Clin Pharmacol.* 2008; 64:43–50. [PubMed: 18040672]
56. Fargue ST, Patterson BE, Bedding AW, et al. Tadalafil pharmacokinetics in healthy subjects. *Br J Clin Pharmacol.* 2006; 61:280–288. [PubMed: 16487221]
57. Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. *Circulation.* 2009; 119:2894–2903. [PubMed: 19470885]
58. Takatsuki S, Calderbank M, Ivy DD. Initial experience with tadalafil in pediatric pulmonary arterial hypertension. *Pediatr Cardiol.* 2012; 33:683–688. [PubMed: 22402804]

59. Wrishko RE, Dingemanse J, Yu A, et al. Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. *J Clin Pharmacol*. 2008; 48:610–618. [PubMed: 18305126]
60. Spence R, Mandagere A, Harrison B, et al. No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers. *J Pharm Sci*. 2009; 98:4962–4974. [PubMed: 19455620]
61. Galiè N, Ghofrani HA, Torbicki A, et al. Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension. *N Engl J Med*. 2005; 353:2148–2157. [PubMed: 16291984]
62. Barst RJ, Ivy DD, Gaitan G, et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naïve children with pulmonary arterial hypertension. *Circulation*. 2012; 125:324–334. [PubMed: 22128226]
63. Barst RJ, Beghetti M, Pulido T, et al. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naïve pediatric pulmonary arterial hypertension. *Circulation*. 2014; 129:1914–1923. [PubMed: 24637559]
64. Vorhies EE, Ivy DD. Drug treatment of pulmonary hypertension in children. *Paediatr Drugs*. 2014; 16:43–65. [PubMed: 24114695]
65. Abman SH, Kinsella JP, Rosenzweig EB, et al. Implications of the U.S. Food and Drug Administration Warning against the Use of Sildenafil for the Treatment of Pediatric Pulmonary Hypertension. *Am J Respir Crit Care Med*. 2013; 187:572–575. [PubMed: 23220921]
66. Fraisse A, Butrous G, Taylor MB, et al. Intravenous sildenafil for postoperative pulmonary hypertension in children with congenital heart disease. *Intensive Care Med*. 2011; 37:502–509. [PubMed: 21069290]
67. Askie LM, Ballard RA, Cutter GR, et al. Inhaled nitric oxide in preterm infants: an individual-patient data meta-analysis of randomized trials. *Pediatrics*. 2011; 128:729–739. [PubMed: 21930540]
68. Roberts JD, Fineman JR, Morin FC, et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group. *N Engl J Med*. 1997; 336:605–610. [PubMed: 9032045]
69. Clark RH, Kueser TJ, Walker MW, et al. Low-dose nitric oxide therapy for persistent pulmonary hypertension of the newborn. Clinical Inhaled Nitric Oxide Research Group. *N Engl J Med*. 2000; 342:469–474. [PubMed: 10675427]
70. Kinsella JP, Neish SR, Ivy DD, et al. Clinical responses to prolonged treatment of persistent pulmonary hypertension of the newborn with low doses of inhaled nitric oxide. *The Journal of Pediatrics*. 1993; 123:103–108. [PubMed: 8320602]
71. Klinger JR. The nitric oxide/cGMP signaling pathway in pulmonary hypertension. *Clin Chest Med*. 2007; 28:143–67. ix. [PubMed: 17338933]
72. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. *Nature*. 1988; 333:664–666. [PubMed: 3131684]
73. Beghetti M, Adatia I. Inhaled nitric oxide and congenital cardiac disease. *CTY*. 2001; 11:142–152.
74. Karamanoukian HL, Glick PL, Zayek M, et al. Inhaled nitric oxide in congenital hypoplasia of the lungs due to diaphragmatic hernia or oligohydramnios. *Pediatrics*. 1994; 94:715–718. [PubMed: 7936901]
75. Miller OI, Tang SF, Keech A, et al. Inhaled nitric oxide and prevention of pulmonary hypertension after congenital heart surgery: a randomised double-blind study. *The Lancet*. 2000; 356:1464–1469.
76. Roberts JD, Lang P, Bigatello LM, et al. Inhaled nitric oxide in congenital heart disease. *Circulation*. 1993; 87:447–453. [PubMed: 8425292]
77. Barst RJ, Channick R, Ivy D, et al. Clinical perspectives with long-term pulsed inhaled nitric oxide for the treatment of pulmonary arterial hypertension. *Pulm Circ*. 2012; 2:139–147. [PubMed: 22837854]
78. Atz AM, Adatia I, Lock JE, et al. Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing. *JACC*. 1999; 33:813–819. [PubMed: 10080486]
79. Balzer DT, Kort HW, Day RW, et al. The INOP Test Study Group. Inhaled Nitric Oxide as a Preoperative Test (INOP Test I). *Circulation*. 2002; 106:I–76–I–81.

80. Day RW, Lynch JM, Shaddy RE, et al. Pulmonary vasodilatory effects of 12 and 60 parts per million inhaled nitric oxide in children with ventricular septal defect. *Am J Cardiol.* 1995; 75:196–198. [PubMed: 7810506]
81. Channick RN, Sitbon O, Barst RJ, et al. Endothelin receptor antagonists in pulmonary arterial hypertension. *JACC.* 2004; 43:62S–67S. [PubMed: 15194180]
82. Barst RJ, Ivy D, Dingemans J, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. *Clin Pharmacol Ther.* 2003; 73:372–382. [PubMed: 12709727]
83. Beghetti M. Bosentan in pediatric patients with pulmonary arterial hypertension. *Curr Vasc Pharmacol.* 2009; 7:225–233. [PubMed: 19356006]
84. Beghetti M, Hoeper MM, Kiely DG, et al. Safety experience with bosentan in 146 children 2–11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program. *Pediatr Res.* 2008; 64:200–204. [PubMed: 18414142]
85. Hislop AA, Moledina S, Foster H, et al. Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children. *Eur Respir J.* 2011; 38:70–77. [PubMed: 21177841]
86. Maiya S, Hislop AA, Flynn Y, et al. Response to bosentan in children with pulmonary hypertension. *Heart.* 2006; 92:664–670. [PubMed: 16216850]
87. Rosenzweig EB, Ivy DD, Widlitz A, et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. *JACC.* 2005; 46:697–704. [PubMed: 16098438]
88. Oudiz RJ, Galiè N, Olschewski H, et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. *JACC.* 2009; 54:1971–1981. [PubMed: 19909879]
89. Galiè N, BADESCH D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. *JACC.* 2005; 46:529–535. [PubMed: 16053970]
90. Beghetti M, Haworth SG, Bonnet D, et al. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study. *Br J Clin Pharmacol.* 2009; 68:948–955. [PubMed: 20002090]
91. Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. *Circulation.* 2008; 117:3010–3019. [PubMed: 18506008]
92. Barst RJ. A review of pulmonary arterial hypertension: role of ambrisentan. *Vascular Health and Risk Management.* 2007; 3:11–22. [PubMed: 17583171]
93. Spence R, Mandagere A, Dufton C, et al. Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers. *J Clin Pharmacol.* 2008; 48:1451–1459. [PubMed: 18832294]
94. Badesch DB, Feldman J, Keogh A, et al. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension. *Cardiovasc Ther.* 2012; 30:93–99. [PubMed: 21884013]
95. Cartin-Ceba R, Swanson K, Iyer V, et al. Safety and efficacy of ambrisentan for the treatment of portopulmonary hypertension. *Chest.* 2011; 139:109–114. [PubMed: 20705798]
96. Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. *J Pharmacol Exp Ther.* 2008; 327:736–745. [PubMed: 18780830]
97. Sidharta PN, van Giersbergen PLM, Halabi A, et al. Macitentan: entry-into-humans study with a new endothelin receptor antagonist. *Eur J Clin Pharmacol.* 2011; 67:977–984. [PubMed: 21541781]
98. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. *The Lancet.* 2001; 358:1119–1123.
99. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. *Eur Respir J.* 2005; 25:244–249. [PubMed: 15684287]
100. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. *N Engl J Med.* 2002; 346:896–903. [PubMed: 11907289]

101. Takatsuki S, Rosenzweig EB, Zuckerman W, et al. Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension. *Pediatr Pulmonol*. 2013; 48:27–34. [PubMed: 22511577]
102. Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. *N Engl J Med*. 2013; 369:809–818. [PubMed: 23984728]
103. Ghofrani H-A, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. *N Engl J Med*. 2013; 369:330–340. [PubMed: 23883378]
104. Ghofrani H-A, D'Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. *N Engl J Med*. 2013; 369:319–329. [PubMed: 23883377]
105. Frey R, Mück W, Kirschbaum N, et al. Riociguat (BAY 63-2521) and warfarin: a pharmacodynamic and pharmacokinetic interaction study. *J Clin Pharmacol*. 2011; 51:1051–1060. [PubMed: 20801938]

Figure 1.

Diller GP, Baumgartner H: Pulmonary arterial hypertension in adults with congenital heart disease. *Int J Clin Pract Suppl* 2010; 64:13–24

Table 1

FDA Approved Vasodilator Therapies

Prostacyclin	Generic Name	Brand Name	Route	FDA Approved Adult Max Dose	Frequency
	Epoprostenol	Flolan® Veletri®	Intravenous	Unknown	continuous
PDE-5 Inhibitor	Iloprost	Ventavis®	Inhaled	5 µg per treatment session	6–9 times daily
	Treprostinil	Remodulin®	Intravenous/Subcutaneous	Unknown	continuous
		Tyvaso®	Inhaled	54 µg per treatment session	4 times daily
		Orenitram®	Oral	Unknown	2–3 times daily
ERA	Sildenafil	Revatio®	Oral	20 mg	3 times daily
	Tadalafil	Adcirca®	Intravenous	10 mg	3 times daily
	Bosentan	Tracleer®	Oral	40 mg	once daily
	Ambrisentan	Letairis®	Oral	125 mg	2 times daily
sGC Stimulator	Macitentan	Opsumit®	Oral	10 mg	once daily
	Riociguat	Adempas®	Oral	10 mg	once daily

PDE-5: Phosphodiesterase type 5. ERA: Endothelin Receptor Antagonist, sGC: Soluble Guanylate Cyclase. None of these medications are FDA approved for pediatric use. Safety and dosing of these medications is not well established in children.

Table 2

Treatment Options for Pediatric Pulmonary Hypertension

	Medication	Dose	Side Effects	Consideration
Prostacyclin	<i>Mechanism of Action: increases cAMP; pulmonary and systemic vasodilation; inhibition of vascular remodeling; antiplatelet aggregation</i>			
	Epoprostenol	Initial infusion rate: 1 – 3 ng/kg/min Maintenance infusion rate: 50 – 80 ng/kg/min	Flushing, headache, nausea, diarrhea, jaw discomfort, rash, hypotension thrombocytopenia	Potential risk of hypotension and bleeding in children receiving concomitant drugs such as anticoagulants, platelet inhibitors, or other vasodilators
	Iloprost	Initial dose: 2.5 µg per inhalation 6 times daily Maintenance dose: 5 µg per inhalation 9 times daily	Cough, wheeze, headache, flushing, jaw pain, diarrhea, rash, hypotension (at higher doses)	Potential risk of exacerbating reactive airway disease
	Treprostinil (IV/SQ)	Initial infusion rate: 1.25 – 2 ng/kg/min Maintenance infusion rate: 50 – 80 ng/kg/min	Flushing, headache, nausea, diarrhea, musculoskeletal discomfort, rash, hypotension, thrombocytopenia, pain at subcutaneous infusion site	Similar to epoprostenol
	Treprostinil (Inhaled)	Initial dose: 3 breaths (18 µg) 4 times daily Maintenance dose: 9 breaths (54 µg) 4 times daily	Cough, headache, nausea, dizziness, flushing, throat irritation	Reactive airway symptoms, hypotension possible at high dose
	Treprostinil (Oral)	Initial dose: 0.25 mg PO BID Maintenance dose: Determined by tolerability	Headache, nausea, diarrhea, jaw pain, extremity pain, hypokalemia, abdominal discomfort, flushing	If BID dosing increment is not tolerated, consider TID dosing
Phosphodiesterase type 5 (PDE-5) Inhibitor	<i>Mechanism of action: inhibits PDE-5; pulmonary vasodilation; inhibition of vascular remodeling</i>			
	Sildenafil	<i>Pediatric (oral):</i> Initial dose: 0.5 mg/kg/dose PO TID Maintenance dose: 1 – 2 mg/kg/dose PO TID <i>Adult (oral):</i> 20 mg PO TID <i>Pediatric (IV):</i> Loading Dose 0.4 mg/kg over 3 hours Followed by continuous infusion: 1.6 mg/kg/day	Headache, flushing, rhinitis, dizziness, hypotension, peripheral edema, dyspepsia, diarrhea, myalgia, back pain	Co-administration of nitrates is contraindicated Sensorineural hearing loss has been reported Ischemic optic neuropathy has been reported
	Tadalafil	<i>Pediatric (preliminary studies suggest):</i> 1 mg/kg/dose PO QD Adult: 40 mg PO QD	Similar to sildenafil No significant effect on vision	Co-administration of nitrates is contraindicated Sensorineural hearing loss has been reported Ischemic optic neuropathy has been reported
Endothelin receptor antagonist (ERA)	<i>Mechanism of action: ET_A/ET_B receptor antagonist, pulmonary vasodilation, inhibition of vascular remodeling</i>			
	Bosentan	<i>Pediatric:</i> 2 mg/kg/dose PO BID 10–20 kg: 31.25 mg PO BID 20–40 kg: 62.5 mg PO BID >40 kg: 125 mg PO BID Adult: Initial dose: 62.5 mg PO BID Maintenance dose: 125 mg PO BID	Abdominal pain, vomiting, extremity pain, fatigue, flushing, headache, edema, nasal congestion, anemia, decreased sperm count Potential risk of dose-dependent increases in aminotransferase levels	Monitor liver enzymes and hemoglobin (required) Not recommended in patients with moderate or severe hepatic impairment Caution with concomitant use of CYP3A4 inducers and inhibitors Teratogenicity * REMS

	Ambrisentan	<i>Pediatric:</i> < 20 kg: 2.5 – 5 mg PO QD > 20 kg: 5 – 10 mg PO QD <i>Adult:</i> Initial dose: 5 mg PO QD Maintenance dose: 10 mg PO QD	Peripheral edema, nasal congestion, headache, flushing, anemia, nausea and decreased sperm count The incidence of serum aminotransferase elevation is low	Obtain baseline liver enzymes and hemoglobin and monitor as clinically indicated Teratogenicity * REMS *
	Macitentan	10 mg PO QD	Nasal congestion, headache, flushing, anemia, decreased sperm count The incidence of serum aminotransferase elevation is low	Obtain baseline liver enzymes and hemoglobin and monitor as clinically indicated Teratogenicity * REMS *
Soluble Guanylate Cyclase (sGC) Stimulator	<i>Mechanism of action: Stimulate sGC, pulmonary vasodilation, inhibition of vascular remodeling</i>			
	Riociguat	Initial dose: 0.5 – 1 mg PO TID Maintenance dose: 2.5 mg PO TID	Headache, dizziness, dyspepsia, nausea, diarrhea, hypotension, vomiting, anemia, gastroesophageal reflux, constipation	Co-administration of nitrates and/or phosphodiesterase-5 inhibitors is contraindicated In growing rats effects on bone formation were observed Teratogenicity * REMS *

* The FDA Amendments Act of 2007 gave the FDA authority to require Risk Evaluation and Mitigation Strategies (REMS) from manufacturers to ensure the benefits of a drug or biological product outweigh its risks. These medications require REMS due to teratogenicity.

None of these medications are FDA approved for pediatric use. Safety and dosing of these medications is not well established in children. Recommended pediatric dosing is included if available.